Advancing CNS Therapy: Cerevance's NETSseq Insights and Precision Drug Development at FENS 2024
Cerevance, a company dedicated to developing targeted therapies for central nervous system (CNS) diseases, is set to present a poster at the Federation of European Neuroscience Societies (FENS) Forum 2024. The event will be hosted in Vienna, Austria, from June 25 to June 29, 2024.
The poster presentation, titled "NETSseq Enhances the Understanding of Cerebellar Transcriptomic Changes in Ataxia-Telangiectasia," will be delivered by Jenna Harvey, PhD, during Poster Session 06 – Section 129 on Friday, June 28th, from 2:00 to 5:30 pm, with the specific poster presentation running from 2:00 to 3:30 pm. The poster number for this session is PS06-28PM-582.
Ataxia-telangiectasia (A-T) is a rare and progressive neurodegenerative disorder caused by mutations in the A-T mutated gene, resulting in a variety of neurological problems. Cerevance has utilized its NETSseq platform to analyze RNA from purified cerebellar cell types of both A-T and control donors. This analysis revealed notable changes in astrocyte gene expression, particularly those linked to inflammation and immune response. Identifying these cell type-specific pathways that are altered by disease provides deeper insights into the molecular mechanisms at play and highlights potential drug targets for future therapies.
Cerevance is at the forefront of developing precision treatments for CNS disorders, including chronic neurodegenerative diseases like Alzheimer’s, Parkinson’s, frontotemporal dementia, and amyotrophic lateral sclerosis. Their work is supported by an extensive repository of over 15,000 human brain tissue samples, which helps generate a comprehensive level of expression and epigenetic data. This data is crucial for pinpointing the most promising targets for new treatments for CNS disorders.
The company employs its proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform and advanced machine learning techniques to discover gene expression profiles in specific cell types. This enables the identification of novel targets uniquely expressed in relevant neural circuits affected by disease or altered in disease states. Cerevance is leveraging this information, along with the expertise of its scientists and drug developers, to advance multiple therapeutics through clinical development.
Among the leading candidates in Cerevance’s pipeline are CVN424, CVN766, and CVN293. CVN424 is a pioneering non-dopamine therapy that has shown promise in improving both motor and non-motor symptoms of Parkinson’s disease and may also delay disease progression. CVN766 is a highly selective antagonist of the orexin 1 receptor and has potential benefits for various psychiatric conditions, including schizophrenia, anxiety/panic, binge eating/obesity, substance use disorder, and Prader-Willi Syndrome. CVN293 is a novel inhibitor of potassium efflux in glia, which plays a role in regulating the inflammasome in people with neurodegenerative diseases.
Cerevance's ambitious pipeline aims to revolutionize the treatment landscape for patients suffering from CNS diseases, providing new hope through innovative and precise therapeutic strategies.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
